Navigation Links
Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus
Date:6/11/2009

- Phase 2 continuation data demonstrated sustained improvement in disease activity and patient response rate through four years of BENLYSTA therapy -

- Frequency of disease flares as measured by the SELENA SLEDAI flare index and by BILAG A or B organ domain scores decreased over four years of BENLYSTA therapy -

- No increase in overall adverse events, serious adverse events, malignancies or serious infections over time -

ROCKVILLE, Md., June 11 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the presentation of results from a long-term Phase 2 continuation trial showing that BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) was associated with sustained improvement in disease activity across multiple clinical measures, decreased frequency of disease flares, and was generally well tolerated through four years on treatment in combination with standard of care in patients with serologically active systemic lupus erythematosus (SLE). The results were presented today in Copenhagen at the 2009 Congress of the European League Against Rheumatism (EULAR).

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

"Based on the results presented at EULAR 2009, the apparent durability of clinical effect and the favorable safety profile observed for belimumab suggest that belimumab has the potential to become an important new treatment for patients with SLE," said Joan T. Merrill, M.D., a study investigator, Program Chair, Clinical Pha
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Printing New Organs: Foundation Funds Medical Technology That Replicates Human Tissue
2. New MIT radio chip mimics human ear
3. deCODE Study Shows Complex Interplay of the Human Biological Clock With Height, Weight and Disease
4. Human Genome Sciences and Novozymes Announce Amendment to Albumin Fusion License Agreement
5. Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments
6. FDA has Granted HUD (Humanitarian Use Device) Designation to ITGIs Pericardium Covered Stents, Over and Under(R) and Aneugraft(R), for Treatment of Perforations and Dissections of Native Coronary Arteries and Saphenous Vein Grafts
7. STEMCELL Technologies Introduces a New Animal Component-Free, Serum-Free Medium for Culturing Human Mesenchymal Stem Cells
8. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
9. Human Genome Sciences to Sponsor Conference Call to Discuss First Quarter 2009 Financial Results
10. The Journal of Cardiac Failure Publishes Results From Celladon Corporations First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure
11. ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Mesenchymal Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... electrons, but one of the most promising technologies for ... on light (photons) instead of electrons. First, it is ... single photons and control their direction. Researchers around the ... this control, but now scientists at the Niels Bohr ... photons emitted one at a time and in a ...
(Date:8/29/2014)... 2014 The global companion diagnostics ... 2019. It is expected to grow at a ... was valued at $1.8 billion in 2013, according ... Research. , For more information regarding analysis details ... The research report, titled “Companion Diagnostics Market (Breast ...
(Date:8/29/2014)... New York (PRWEB) August 29, 2014 According ... “Global Orthobiologics Market” the global orthobiologics market was valued at ... a market worth USD 5,519.9million in 2019at a CAGR of ... population aged 50 years and above is afflicted by bone ... double by the year 2020. This has and will continue ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Pittcon is ... MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, have organized ... September 5, 2014. JASIS , Asia’s largest analytical ... 2014, in Makuhari Messe, Japan. , The four ... for Bioanalysis from Single Molecules to Single Cells” will ...
Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2
... Biotech Products, L.P. today announced that data related to ... Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, ... The studies were sponsored by Centocor Ortho Biotech Products, ... and Development, a unit of Johnson & Johnson Pharmaceutical ...
... 28 Plexus Corp. (Nasdaq: PLXS ) announced ... generation automated screening system for the pre-processing of human papillomavirus ... solution to a current manual process, through sophisticated robotic motions. ... for HPV; a virus that has an established link to ...
... Next step toward deploying biometric exit procedures for ... of Homeland Security (DHS) today began collecting biometrics ... citizens departing the United States as part of ... and Detroit Metropolitan Wayne County Airport. Since 2004, ...
Cached Biology Technology:Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 7Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 8Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 9Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 10Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 11Plexus Awarded Development Contract With QIAGEN 2Plexus Awarded Development Contract With QIAGEN 3Plexus Awarded Development Contract With QIAGEN 4DHS Begins Test of Biometric Exit Procedures at Two U.S. Airports 2
(Date:8/29/2014)... Ebola researcher from the University of Texas Medical Branch at ... three monoclonal antibodies can completely protect monkeys against a lethal ... at a time when the disease is severe. , Thomas ... for Nature discussing advances in Ebola treatment research. ... among the most deadly of pathogens, with fatality rates of ...
(Date:8/29/2014)... understand how the repeated climatic shifts over the ... of genetic diversity, a team of researchers led ... Ana Carnaval developed a new biodiversity metric called ... which the genetic variation within species is restricted ... professor of biology, and 14 other researchers from ...
(Date:8/29/2014)... type and number of connections in transcription factor networks ... in a study published in PLOS Computational Biology ... assortativity signature contributes to a network,s resilience against mutations. ... out-out assortativity of TFN models has a greater effect ... types of assortativity," said Dov A. Pechenick, PhD, lead ...
Breaking Biology News(10 mins):Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2CCNY team defines new biodiversity metric 2Assortativity signatures of transcription factor networks contribute to robustness 2
... has provided the first conclusive evidence that neurodevelopmental ... such as Alzheimer's disease, Parkinson's disease and ataxias ... specific gene defects that interfere with the electrical ... neurons. , The implicated gene, KCNC3, and two ...
... evolution of Earth's first animals will have to be ... according to a new study by Indiana University Bloomington ... of the National Academy of Sciences. , Purported ... last 12 years, mainly by paleontologists working in China. ...
... not only make teens more aggressive, but may keep ... ultimately wears off but there may be other, lasting ... in February's Behavioral Neuroscience, also showed that aggression rose ... the brain's aggression control region. Behavioral Neuroscience is ...
Cached Biology News:Study ties 'new' cell-death mechanism to developmental and degenerative brain disorders 2Study ties 'new' cell-death mechanism to developmental and degenerative brain disorders 3Embryos tell story of Earth's earliest animals 2Embryos tell story of Earth's earliest animals 3Animal models show that anabolic steroids flip the adolescent brain's switch for aggression 2Animal models show that anabolic steroids flip the adolescent brain's switch for aggression 3
... which can immunocapture up to 50 g ... included are 2 mg of bovine heart ... immunocapture kit allows isolation of the ATP ... of tissue. This facilitates subsequent analysis of ...
ASCIZ...
Anti-Flavocytochrome b Monoclonal, FITC Labeled Research Focus: other Storage: 4C Shipping Temperature: 4C...
Chaps Cell Extract Buffer can be used to lyse cells under nondenaturing conditions and is recommendedfor the preparation of cell lysates to be used with our caspase signaling pathway antibodies...
Biology Products: